Nodus Oncology Ltd. presented the discovery of NODX-010, a potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor being developed for the potential treatment of cancer, including tumors resistant to PARP inhibitors.
The University of Wisconsin-Madison has synthesized a next-generation prostate-specific member antigen (PSMA)-targeting small molecule, ART-101, for the treatment of advanced prostate cancer.
Retinitis pigmentosa (RP) is the most common hereditary degenerative eye disease that leads to progressive vision loss, primarily caused by retinal degeneration.
Although antifibrotic agents can contribute to suppressing renal function decline when administered in combination with existing treatments for chronic kidney disease, drugs targeting kidney fibrosis have yet to reach the clinic.
More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion protein BCR-ABL1. The first-generation ABL tyrosine kinase inhibitor (TKI) Gleevec (imatinib) has significantly enhanced the prognosis of CML patients.
Researchers from Adipo Therapeutics LLC presented data from preclinical studies that aimed to assess the γ-secretase inhibitor ADPO-002 (dibenzazepine) for the treatment of obesity.
RSS
